Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | CMA1 | P23946 | 18/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL584454 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951857 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL10694935 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL9800360 | 0.99 | PTGS1 (0.97) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194013 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL14196602 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194012 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49016 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49017 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL3382938 | 0.92 | PTGS1 (0.87) | PTGS1HSD17B10TDP1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173456-A1 | THERAPEUTIC COMPOSITIONS FOR WOUND TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| WO-2023201345-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023137320-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230201167-A1 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4110330-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11344652-B2 | Ionic liquids that sterilize and prevent biofilm formation in skin wound healing devices | THE ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021195661-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021050564-A2 | THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF LYME DISEASE AND LYME DISEASE-RELATED DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
| US-10900043-B2 | Compositions and methods for treating bacterial disease | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-01-26 | — | — | US | disclosed |
| EP-1212055-A4 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040229857-A1 | Neurotherapeutic composition and method | REVAAX PHARMACEUTICALS, LLC | 2004-11-18 | — | — | US | disclosed |
| US-6627625-B1 | Beta-lactam antibiotics and beta -lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter by anxiolytic and antiaggressive behavior modification ans enhanced cognition | REVAAX PHARMACEUTICALS, LLC | 2003-09-30 | — | — | US | disclosed |
| US-20030158172-A1 | Neurotherapeutic composition and method therefor | KOPPEL GARY A (US) | 2003-08-21 | — | — | US | disclosed |
| US-6489319-B2 | PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS | REVAAX PHARMACEUTICALS, LLC | 2002-12-03 | — | — | US | disclosed |
| WO-2002064087-A2 | NEUROTHERAPEUTIC USE OF CARBOXYPEPTIDASE INHIBITORS | REVAAX PHARMACEUTICALS, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1212055-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | Revaax Pharmaceuticals LLC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020028761-A1 | Neurotherapeutic use of carboxypeptidase inhibitors | REVAAX PHARMACEUTICALS, LLC | 2002-03-07 | — | — | US | disclosed |
| WO-2001012184-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS, LLC (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-0091502-A1 | A pharmaceutical preparation of cephalosporin for rectal administration | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028761-A1 | Neurotherapeutic use of carboxypeptidase inhibitors | THOP1, DPEP1, PREP | PTGS1 839/4885HSD17B10 1559/4885TDP1 124/4885 |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, SARS1 | PTGS1 841/4885HSD17B10 2105/4885TDP1 1663/4885 |
| US-20030158172-A1 | Neurotherapeutic composition and method therefor | ANPEP, PREP, MME | PTGS1 950/4885HSD17B10 2060/4885TDP1 2165/4885 |
| US-20040229857-A1 | Neurotherapeutic composition and method | ACHE, BDNF, PYGB | PTGS1 2155/4885HSD17B10 1033/4885TDP1 523/4885 |
| US-20230201167-A1 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, MAVS | PTGS1 597/4885HSD17B10 2827/4885TDP1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.